Cite
TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer.
MLA
Shao, Xinyi, et al. “TH-4000, a Hypoxia-Activated Pan-HER Inhibitor, Shows Excellent Preclinical Efficacy for the Treatment of HER2+ Breast Cancer.” Archives of Toxicology, vol. 98, no. 3, Mar. 2024, pp. 865–81. EBSCOhost, https://doi.org/10.1007/s00204-023-03670-6.
APA
Shao, X., Yang, D., Shan, L., Yan, X., Xu, D., Li, L., Sun, Y., Yu, Q., Zhou, H., Ding, Y., & Tang, J. (2024). TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer. Archives of Toxicology, 98(3), 865–881. https://doi.org/10.1007/s00204-023-03670-6
Chicago
Shao, Xinyi, Dawei Yang, Liuqun Shan, Xueqin Yan, Di Xu, Lei Li, Yidan Sun, et al. 2024. “TH-4000, a Hypoxia-Activated Pan-HER Inhibitor, Shows Excellent Preclinical Efficacy for the Treatment of HER2+ Breast Cancer.” Archives of Toxicology 98 (3): 865–81. doi:10.1007/s00204-023-03670-6.